TECH Form 4: Director Exercises 17,040 Options and Sells Same Amount
Rhea-AI Filing Summary
Roeland Nusse, a director of Bio-Techne Corporation (TECH), reported option exercises and share sales on 08/25/2025. He exercised 17,040 stock options with an exercise price of $21.84 and simultaneously sold 17,040 common shares at a weighted average price of $56.3608, reducing his reported beneficial ownership to 44,559 shares. Table II shows Nusse retains multiple outstanding option grants exercisable into common stock, including 17,040 options exercisable through 10/28/2025 and other option tranches with exercise prices from $25.30 to $128.81. The Form 4 was submitted via attorney-in-fact on 08/27/2025.
Positive
- Transparent disclosure of exercise, sale, weighted average sale price, and option vesting terms
- Director retains significant equity and option exposure after the transactions (44,559 shares plus multiple outstanding options)
Negative
- Reported beneficial ownership decreased following sale of 17,040 shares
- Insider sale of exercised shares could be perceived as unlocking personal liquidity
Insights
TL;DR: Routine insider option exercise with concurrent sale; principal effect is modest reduction in reported holdings.
The filing documents a common pattern where an insider exercises vested options at $21.84 and sells the same number of shares at a materially higher weighted average price ($56.3608). This realizes value for the reporting person while leaving significant remaining equity and option exposure. The reported beneficial ownership declined to 44,559 shares, but the director still holds multiple option tranches across years, preserving upside participation. The transaction appears procedural rather than signaling a material corporate event.
TL;DR: Disclosure is complete and timely; transaction was reported by attorney-in-fact and includes explanatory footnotes.
The Form 4 includes required details: transaction codes, weighted average sale price footnote, option vesting mechanics, and an attorney-in-fact signature dated 08/27/2025. The filing clarifies that the sale price is a weighted average across multiple trades and discloses vesting terms for the most recent option grant. From a governance standpoint this meets SEC reporting expectations and provides transparency on insider liquidity and remaining equity incentives.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Options (Right to Buy) | 17,040 | $0.00 | -- |
| Exercise | Common Stock | 17,040 | $21.84 | $372K |
| Sale | Common Stock | 17,040 | $56.3608 | $960K |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.21 to $56.33 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders.
